Koca Yıldırım Hande Esra, Özgürlük İzzet, Ersak Burak, Yüksel Dilek, Turmuş Eyüp Gökhan, Yeşil Baran, Kılıç Çiğdem, Koç Sevgi, Boran Nurettin, Sucu Sadun, Çakır Caner
Department of Gynecologic Oncology, Ümraniye Training and Research Hospital, 34764 İstanbul, Turkey.
Department of Obstetrics and Gynecology, Ankara Bilkent City Hospital, 06800 Ankara, Turkey.
J Clin Med. 2025 Mar 7;14(6):1791. doi: 10.3390/jcm14061791.
Serous epithelial ovarian cancer is typically diagnosed at an advanced stage and often recurs following treatment. Isolated organ recurrence is rare in this disease, making treatment planning a critical decision. Therefore, we investigated the survival rates of patients who developed isolated liver recurrence. : The entire cohort included patients who underwent cytoreductive surgery between January 1993 and December 2020. We evaluated patients who completed primary chemotherapy after cytoreductive surgery based on their status of isolated liver recurrence. We created two groups: patients with isolated parenchymal recurrence and patients with isolated capsular recurrence. Staging was based on the International Federation of Gynecology and Obstetrics (FIGO) 2014 staging criteria. For patients treated before 2014, cancer staging was adapted to the FIGO 2014 system based on a surgical and pathological assessment. The mean ages of patients with liver capsule and parenchymal recurrence at the time of primary surgery were 47 ± 10.6 and 49 ± 8.9 years, respectively. The median recurrence of patients with capsular recurrence was 13 (2-70) months. In patients with parenchymal recurrence, the duration was 10 months (4-80) and was statistically insignificant. While survival was 41.5 (5-120) months in patients with capsular recurrence, it was 34 (12-120) months in patients with parenchymal recurrence, but there was no statistical difference. In our 27 years' of experience with EOC management, we have studied patients with isolated liver recurrences. The finding that either capsular or parenchymal liver recurrence has no significant impact on overall survival suggests that both types of recurrence can be managed with similar treatment and follow-up approaches. This observation could simplify patient management and improve outcomes by allowing clinicians to focus on optimal surgical and systemic treatment strategies rather than the anatomic pattern of recurrence.
浆液性上皮性卵巢癌通常在晚期被诊断出来,并且在治疗后常常复发。在这种疾病中,孤立器官复发很少见,这使得治疗计划成为一个关键决策。因此,我们调查了发生孤立性肝复发患者的生存率。整个队列包括1993年1月至2020年12月期间接受细胞减灭术的患者。我们根据孤立性肝复发状态评估了细胞减灭术后完成一线化疗的患者。我们创建了两组:孤立实质复发患者和孤立包膜复发患者。分期基于国际妇产科联盟(FIGO)2014年分期标准。对于2014年前接受治疗的患者,根据手术和病理评估将癌症分期调整为FIGO 2014系统。初次手术时肝包膜和实质复发患者的平均年龄分别为47±10.6岁和49±8.9岁。包膜复发患者的中位复发时间为13(2 - 70)个月。实质复发患者的持续时间为10个月(4 - 80),且无统计学意义。包膜复发患者的生存期为41.5(5 - 120)个月,实质复发患者为34(12 - 120)个月,但无统计学差异。在我们27年的上皮性卵巢癌管理经验中,我们研究了孤立性肝复发患者。肝包膜或实质复发对总生存期均无显著影响这一发现表明,两种类型的复发都可以采用相似的治疗和随访方法进行管理。这一观察结果可以简化患者管理,并通过让临床医生专注于最佳的手术和全身治疗策略而非复发的解剖模式来改善治疗结果。